Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbbVie

190.58
+4.192.25%
Post-market: 190.30-0.2800-0.15%19:41 EDT
Volume:6.20M
Turnover:1.18B
Market Cap:336.64B
PE:81.45
High:191.39
Open:186.92
Low:186.50
Close:186.39
Loading ...

AbbVie's migraine drug meets main goal of late-stage study

Reuters
·
18 Jun

AbbVie Inc. Announces Positive Phase 3 Study Results for Atogepant in Migraine Prevention

Reuters
·
18 Jun

Abbvie Inc - Atogepant Achieves Primary and Secondary Endpoints in Phase 3 Study

THOMSON REUTERS
·
18 Jun

Abbvie Announces New Data Demonstrating Atogepant (Qulipta® / Aquipta®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

THOMSON REUTERS
·
18 Jun

AbbVie Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
18 Jun

Medincell SA Reports 2.8x Increase in Revenues to €25.4M, Net Loss Improves by 26% to €18.4M in 2024-25 Results

Reuters
·
17 Jun

AbbVie (ABBV) Announces Unsuccessful Phase 3 Trial for Blood Cancer Drug

TIPRANKS
·
17 Jun

BUZZ-AbbVie stock dips after cancer drug trial setback

Reuters
·
16 Jun

Roche, AbbVie says Phase III VERONA study faliled in MDS

TIPRANKS
·
16 Jun

AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint

TIPRANKS
·
16 Jun

AbbVie Inc. Announces VERONA Trial Results: Venetoclax Combination Falls Short on Improving Overall Survival in Higher-Risk Myelodysplastic Syndrome

Reuters
·
16 Jun

Abbvie Inc - Verona Trial Data Does Not Impact Current Venetoclax Indications

THOMSON REUTERS
·
16 Jun

Abbvie Provides Update on Verona Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

THOMSON REUTERS
·
16 Jun

Abbvie Inc - Verona Trial for Hr-Mds Did Not Meet Primary Endpoint

THOMSON REUTERS
·
16 Jun

Abbvie Inc - No New Safety Signals Observed in Verona Trial

THOMSON REUTERS
·
16 Jun

Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)

TIPRANKS
·
13 Jun

Balanced Outlook for AbbVie: Hold Rating Amid Opportunities and Challenges

TIPRANKS
·
13 Jun

Senators Propose Ban on Drug Advertising to Consumers -- Update

Dow Jones
·
13 Jun

FDA Approves AbbVie's MAVYRET® for Expanded Use in Treating Acute Hepatitis C, Supporting Global Disease Elimination Goals

Reuters
·
12 Jun

U.S. FDA Approves Expanded Indication for Abbvie's Mavyret® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People With Acute Hepatitis C Virus

THOMSON REUTERS
·
12 Jun